ZIOPHARM Oncology (NASDAQ: ZIOP) and Dipexium Pharmaceuticals (NASDAQ:PLXP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.

Institutional and Insider Ownership

41.9% of ZIOPHARM Oncology shares are owned by institutional investors. Comparatively, 19.7% of Dipexium Pharmaceuticals shares are owned by institutional investors. 10.4% of ZIOPHARM Oncology shares are owned by insiders. Comparatively, 47.7% of Dipexium Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for ZIOPHARM Oncology and Dipexium Pharmaceuticals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ZIOPHARM Oncology 0 1 2 0 2.67
Dipexium Pharmaceuticals 0 1 1 0 2.50

ZIOPHARM Oncology presently has a consensus target price of $16.50, indicating a potential upside of 152.29%. Given ZIOPHARM Oncology’s stronger consensus rating and higher possible upside, equities analysts clearly believe ZIOPHARM Oncology is more favorable than Dipexium Pharmaceuticals.

Volatility & Risk

ZIOPHARM Oncology has a beta of 1.64, indicating that its stock price is 64% more volatile than the S&P 500. Comparatively, Dipexium Pharmaceuticals has a beta of 1.84, indicating that its stock price is 84% more volatile than the S&P 500.

Earnings & Valuation

This table compares ZIOPHARM Oncology and Dipexium Pharmaceuticals’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
ZIOPHARM Oncology $6.39 million 143.93 -$48.70 million ($0.50) -13.08
Dipexium Pharmaceuticals $375,950.00 147.90 -$8.09 million N/A N/A

Dipexium Pharmaceuticals has higher revenue, but lower earnings than ZIOPHARM Oncology.

Profitability

This table compares ZIOPHARM Oncology and Dipexium Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ZIOPHARM Oncology -789.28% N/A -45.35%
Dipexium Pharmaceuticals N/A -122.35% -91.84%

Summary

ZIOPHARM Oncology beats Dipexium Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

ZIOPHARM Oncology Company Profile

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. It has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.

Dipexium Pharmaceuticals Company Profile

PLx Pharma Inc., formerly Dipexium Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is a late stage specialty pharmaceutical company focusing on commercializing its lead products: Aspertec 325 mg and Aspertec 81 mg (Aspertec). The Company’s products and technology includes PLxGuard delivery system, Aspertec 325 mg, PL1100/PL1200 Ibuprofen. PLxGuard delivery system uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs to selectively release these drugs to targeted portions of the GI tract. The Company’s lead product Aspertec 325 mg is a liquid-fill aspirin capsule for prevention of cardiovascular disease. Through PLxGuard delivery system the Company creates a lipid-based formulation of ibuprofen, PL1200 Ibuprofen Capsules, 200 mg.

Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.